Literature DB >> 24403076

Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.

Julia E Maxson1, Samuel B Luty, Jason D MacManiman, Melissa L Abel, Brian J Druker, Jeffrey W Tyner.   

Abstract

Mutations in the CSF3 granulocyte colony-stimulating factor receptor CSF3R have recently been found in a large percentage of patients with chronic neutrophilic leukemia and, more rarely, in other types of leukemia. These CSF3R mutations fall into two distinct categories: membrane-proximal mutations and truncation mutations. Although both classes of mutation have exhibited the capacity for cellular transformation, several aspects of this transformation, including the kinetics, the requirement for ligand, and the dysregulation of downstream signaling pathways, have all been shown to be discrepant between the mutation types, suggesting distinct mechanisms of activation. CSF3R truncation mutations induce overexpression and ligand hypersensitivity of the receptor, likely because of the removal of motifs necessary for endocytosis and degradation. In contrast, little is known about the mechanism of activation of membrane-proximal mutations, which are much more commonly observed in chronic neutrophilic leukemia. In contrast with CSF3R truncation mutations, membrane-proximal mutations do not exhibit overexpression and are capable of signaling in the absence of ligand. We show that the Thr-615 and Thr-618 sites of membrane-proximal mutations are part of an O-linked glycosylation cluster. Mutation at these sites prevents O-glycosylation of CSF3R and increases receptor dimerization. This increased dimerization explains the ligand-independent activation of CSF3R membrane-proximal mutations. Cytokine receptor activation through loss of O-glycosylation represents a novel avenue of aberrant signaling. Finally, the combination of the CSF3R membrane proximal and truncation mutations, as has been reported in some patients, leads to enhanced cellular transformation when compared with either mutation alone, underscoring their distinct mechanisms of action.

Entities:  

Keywords:  Cytokine; GCSFR T595I; Glycoprotein; Leukemia; Myeloproliferative Neoplasm; Neutrophil; Receptor Modification

Mesh:

Substances:

Year:  2014        PMID: 24403076      PMCID: PMC3937653          DOI: 10.1074/jbc.M113.508440

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase.

Authors:  Muneyoshi Futami; Quan-Sheng Zhu; Zakary L Whichard; Ling Xia; Yuehai Ke; Benjamin G Neel; Gen-Sheng Feng; Seth J Corey
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Granulocyte colony-stimulating factor receptor T595I (T618I) mutation confers ligand independence and enhanced signaling.

Authors:  H M Mehta; T Glaubach; A Long; H Lu; B Przychodzen; H Makishima; M A McDevitt; N C P Cross; J Maciejewski; S J Corey
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528

3.  Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia.

Authors:  Renée Beekman; Marijke Valkhof; Paulette van Strien; Peter J M Valk; Ivo P Touw
Journal:  Haematologica       Date:  2013-03-18       Impact factor: 9.941

4.  Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Authors:  Renée Beekman; Marijke G Valkhof; Mathijs A Sanders; Paulette M H van Strien; Jurgen R Haanstra; Lianne Broeders; Wendy M Geertsma-Kleinekoort; Anjo J P Veerman; Peter J M Valk; Roel G Verhaak; Bob Löwenberg; Ivo P Touw
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

5.  Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics.

Authors:  Lambertus H J Aarts; Onno Roovers; Alister C Ward; Ivo P Touw
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

6.  An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia.

Authors:  Louisa V Forbes; Rosemary E Gale; Arnold Pizzey; Karin Pouwels; Amit Nathwani; David C Linch
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

7.  G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses.

Authors:  Quan-Sheng Zhu; Lisa J Robinson; Vera Roginskaya; Seth J Corey
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

8.  CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

Authors:  A Pardanani; T L Lasho; R R Laborde; M Elliott; C A Hanson; R A Knudson; R P Ketterling; J E Maxson; J W Tyner; A Tefferi
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

9.  SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling.

Authors:  Akiko Kimura; Ichiko Kinjyo; Yumiko Matsumura; Hiroyuki Mori; Ryuichi Mashima; Mine Harada; Kenneth R Chien; Hideo Yasukawa; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

View more
  25 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  Next-generation sequencing-based panel testing for myeloid neoplasms.

Authors:  Frank C Kuo; Fei Dong
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  De novo expression of human polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium.

Authors:  Kirstine Lavrsen; Sally Dabelsteen; Sergey Y Vakhrushev; Asha M R Levann; Amalie Dahl Haue; August Dylander; Ulla Mandel; Lars Hansen; Morten Frödin; Eric P Bennett; Hans H Wandall
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

4.  The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Authors:  Julia E Maxson; Samuel B Luty; Jason D MacManiman; Jason C Paik; Jason Gotlib; Peter Greenberg; Swaleh Bahamadi; Samantha L Savage; Melissa L Abel; Christopher A Eide; Marc M Loriaux; Emily A Stevens; Jeffrey W Tyner
Journal:  Clin Cancer Res       Date:  2015-10-16       Impact factor: 12.531

5.  CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.

Authors:  Julia E Maxson; Rhonda E Ries; Yi-Cheng Wang; Robert B Gerbing; E Anders Kolb; Sarah L Thompson; Jaime M Guidry Auvil; Marco A Marra; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard Moore; William Long; Patee Gesuwan; Tanja M Davidsen; Leandro C Hermida; Seamus B Hughes; Jason E Farrar; Jerald P Radich; Malcolm A Smith; Daniela S Gerhard; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  Blood       Date:  2016-05-03       Impact factor: 22.113

6.  Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

Authors:  Haijiao Zhang; Cody Coblentz; Kevin Watanabe-Smith; Sophie Means; Jasmine Means; Julia E Maxson; Jeffrey W Tyner
Journal:  J Biol Chem       Date:  2018-03-23       Impact factor: 5.157

7.  Immature truncated O-glycophenotype of cancer directly induces oncogenic features.

Authors:  Prakash Radhakrishnan; Sally Dabelsteen; Frey Brus Madsen; Chiara Francavilla; Katharina L Kopp; Catharina Steentoft; Sergey Y Vakhrushev; Jesper V Olsen; Lars Hansen; Eric P Bennett; Anders Woetmann; Guangliang Yin; Longyun Chen; Haiyan Song; Mads Bak; Ryan A Hlady; Staci L Peters; Rene Opavsky; Christenze Thode; Klaus Qvortrup; Katrine T-B G Schjoldager; Henrik Clausen; Michael A Hollingsworth; Hans H Wandall
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-12       Impact factor: 11.205

8.  Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.

Authors:  Haijiao Zhang; Sophie Means; Anna Reister Schultz; Kevin Watanabe-Smith; Bruno C Medeiros; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Tim Kükenshöner; Oliver Hantschel; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2017-06-26       Impact factor: 12.701

9.  Probing the contribution of individual polypeptide GalNAc-transferase isoforms to the O-glycoproteome by inducible expression in isogenic cell lines.

Authors:  John Hintze; Zilu Ye; Yoshiki Narimatsu; Thomas Daugbjerg Madsen; Hiren J Joshi; Christoffer K Goth; Adam Linstedt; Collin Bachert; Ulla Mandel; Eric P Bennett; Sergey Y Vakhrushev; Katrine T Schjoldager
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

10.  Functional genomics for personalized cancer therapy.

Authors:  Jeffrey W Tyner
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.